Davide Campana
Overview
Explore the profile of Davide Campana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
1685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masciangelo G, Campana D, Ricci C, Andrini E, Rakichevikj E, Fusaroli P, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996913
Pancreatic neuroendocrine neoplasms (pNENs) represent approximately 2% of all solid pancreatic tumors. The incidence of pNENs has been increasing in the last decade. The clinical manifestations of pNENs range from...
2.
The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms - A systematic review
Arrivi G, Fazio N, Tafuto S, Falconi M, Carnaghi C, Campana D, et al.
Cancer Treat Rev
. 2025 Feb;
134:102899.
PMID: 39954330
Pancreatic neuroendocrine tumors (pan-NETs) represent a highly heterogeneous and complex pathology, with therapeutic management and prognosis influenced by several biological and clinical characteristics. Chemotherapy, including regimens based on capecitabine and...
3.
Nigro M, Marchetti A, Fumagalli E, De Luca I, Bertuzzi A, Grimaudo M, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2456058.
PMID: 39853981
Importance: The D842V platelet-derived growth factor receptor α (PDGFRA) mutation identifies a molecular subgroup of gastrointestinal stromal tumors (GISTs), primarily resistant to standard tyrosine kinase inhibitors and with an overall...
4.
Galvani L, Zappi A, Pusceddu S, Gelsomino F, La Salvia A, Oldani S, et al.
Endocrine
. 2025 Jan;
PMID: 39853630
Background: Lung neuroendocrine neoplasms (NENs) represent about 20% of all lung cancers. Few therapeutic options are available for atypical carcinoids (ACs). Single-agent temozolomide (TEM) is active in lung NENs, but...
5.
Lamberti G, Campana D
Nat Rev Dis Primers
. 2025 Jan;
11(1):7.
PMID: 39848965
No abstract available.
6.
Polici M, Caruso D, Masci B, Marasco M, Valanzuolo D, DellUnto E, et al.
J Neuroendocrinol
. 2024 Nov;
37(1):e13472.
PMID: 39564809
To evaluate a radiomic strategy for predicting progression in advanced gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients treated with somatostatin analogs (SSAs). Fifty-eight patients with GEP-NETs and liver metastases, with baseline computerized...
7.
Clarizio G, Merli Y, Campana D, Corti B, Agostinelli C, Pileri A
Ital J Dermatol Venerol
. 2024 Jul;
159(5):579-581.
PMID: 39039955
No abstract available.
8.
Mainetti M, Aprile M, Campana D, Marchetti F
Recenti Prog Med
. 2024 Jul;
115(7):361-365.
PMID: 39011919
Well-differentiated neuroendocrine tumors of the appendix (NETs) are rare in pediatric and adolescent age groups. However, they are the most common gastrointestinal epithelial tumor in this age group and the...
9.
β1600 Q.Clear Digital Reconstruction of [Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients
Di Franco M, Fortunati E, Zanoni L, Bonazzi N, Mosconi C, Malizia C, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999406
Image reconstruction is crucial for improving overall image quality and diagnostic accuracy. Q.Clear is a novel reconstruction algorithm that reduces image noise. The aim of the present study is to...
10.
Andrini E, Ricco G, Zappi A, Aloi S, Giordano M, Altimari A, et al.
Cancer Treat Rev
. 2024 Jul;
129:102798.
PMID: 38970838
Small-cell lung cancer (SCLC), accounting for 10-20 % of all lung tumors, represents the most aggressive high-grade neuroendocrine carcinoma. Most patients are diagnosed with extensive-stage SCLC (ES-SCLC), with brian metastases...